Description: Synaptogenix is a clinical-stage biopharmaceutical company that has historically worked to develop novel therapies for neurodegenerative diseases. Synaptogenix has conducted clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in Alzheimer's disease. Preclinical studies have also demonstrated Bryostatin's regenerative mechanisms of action for the rare disease, Fragile X syndrome, and for other neurodegenerative disorders such as multiple sclerosis, stroke, and traumatic brain injury. The U.S. Food and Drug Administration has granted Orphan Drug Designation to Synaptogenix for Bryostatin-1 as a treatment for Fragile X syndrome. Bryostatin-1 has already undergone testing in more than 1,500 people in cancer studies, thus creating a large safety data base that will further inform clinical trial designs.
Home Page: www.synaptogen.com
SNPX Technical Analysis
1185 Avenue of the Americas
New York,
NY
10036
United States
Phone:
973 242 0005
Officers
| Name | Title |
|---|---|
| Dr. Alan J. Tuchman M.D., MBA(FAAN) | CEO & Director |
| Dr. Daniel L. Alkon M.D. | Pres, Chief Scientific Officer & Director |
| Mr. Robert Weinstein | CFO, Sec. & Exec. VP |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.4396 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2020-12-08 |
| Fiscal Year End: | December |
| Full Time Employees: | 4 |